CIBC Bancorp USA’s Moderna MRNA Stock Holding History

CIBC Bancorp USA’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.4M	Sell	91,461 -7,054	-7%	-$365K	0.01%	670
2026 Q1	$5M	Buy	+98,515	New	+$4.6M	0.01%	705
2025 Q3	$913K	Buy	+35,359	New	+$986K	0.01%	696

Other funds holding MRNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CIBC Bancorp USA's MRNA Position: Q2 2026 in Review

CIBC Bancorp USA reduced its Moderna (MRNA) stake by 7.2% in Q2 2026, selling an estimated $365K and leaving 91,461 shares worth $6.4M. The position accounts for 0.01% of the portfolio, ranked #670.

CIBC Bancorp USA first reported a position in MRNA in Q3 2025 and has held it in 3 quarters since. 730 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

CIBC Bancorp USA held 91,461 shares of Moderna worth $6.4M as of Q2 2026.
CIBC Bancorp USA sold 7,054 Moderna shares in Q2 2026, an estimated $365K.
Moderna made up 0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #670 holding.
CIBC Bancorp USA first reported a position in Moderna in Q3 2025 and has held it in 3 quarters since.
730 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.